Intravenous Iron Drugs Market Projected to Hit $8.71 Billion by 2035 – SNS Insider

Growing prevalence of chronic diseases, increasing preference for IV iron over oral therapies, and strong U.S. market leadership drive global expansion at 9.31% CAGR.Austin, United States, March 26, ...
Business Wire

American Regent Expands Promotional Campaign for Iron Deficiency Anemia Drug Injectafer ® (Ferric Carboxymaltose Injection)

First and only high-dose intravenous iron for iron deficiency anemia of various etiologies SHIRLEY, N.Y.--(BUSINESS WIRE)--American Regent, Inc., a subsidiary of Luitpold Pharmaceuticals, Inc. (a ...
Healio

Risk for anaphylaxis from IV iron overall ‘very low,’ but varies between formulations

Please provide your email address to receive an email when new articles are posted on . The risk for anaphylaxis from IV iron formulations appeared low, although it varied depending on the type of ...
Healio

IV iron most cost-effective for iron deficiency anemia, heavy menstrual bleeding

Please provide your email address to receive an email when new articles are posted on . IV iron is the most cost-effective option for women with iron deficiency anemia and heavy menstrual bleeding.
Monthly Prescribing Reference

IV Iron Dextran Cost-Effective for Managing Iron-Deficiency Anemia

IV iron dextran was the most cost-effective treatment, yielding 19.26 quality-adjusted life years at a cost of $157,500 vs 19.10 costing $152,900 for oral ferrous sulfate. HealthDay News — Intravenous ...
Renal & Urology News

IV Iron Dextran Cost-Effective for Managing Iron-Deficiency Anemia

IV iron dextran is most cost-effective, yielding 19.26 QALYs compared with 19.10 QALYs for oral ferrous sulfate. (HealthDay News) — Intravenous (IV) iron dextran is the most cost-effective strategy ...